Next Phase Newsletter

The firm is a private investment firm based in New York, NY. The firm launched the Health Tech Fund in 2012 to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The Health Tech Fund focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a Japanese technology-based distributor and service solution provider of electronic components, enterprise IT and innovative solutions. Headquartered in Japan, the company operates 85 offices worldwide. The firm’s main business domains lie in semiconductors, IoT and cybersecurity, but seeks to expand beyond these realms to create new businesses, including healthcare, life sciences. The firm has been making strategic investments periodically to make business partnership with external technology startups from all around the world that align with the firm’s interests. The firm’s investment is stage agnostic but mostly between Seed and Series B financing rounds. The firm is open to business partnership and global investment opportunities from any country.

Within life sciences and healthcare, the firm is open to opportunities in digital therapeutics, devices, and digital health. Within therapeutics, the firm is primarily seeking enabling technologies in chronic diseases as diabetes, sleep disorders, mental health, and also depression and dementia. The firm will generally not consider opportunities such as pre-clinical antibody or small molecule assets that require a long window. The firm is also interested in devices (open to both 510k and PMA) or digital health technologies that are in the fields of primary care, elderly care, and mental health. Some examples of The firm’s investments include a continuous glucose monitoring device, an AI-driven robotics platform for chronic care management, and a digital therapeutics app for chronic diseases. While the firm can invest in very early-stage companies, the firm prefers to invest in companies with a viable product that is ready to be tested in pilots or clinical trials at the earliest. The firm does not

expect companies to have already received FDA approval and will help companies go through the regulatory process. Furthermore, the firm has an ongoing strategic partnership with the Japanese Organization for Medical Device Development (JOMDD), through which the firm helps companies with PMDA approval in Japan.

The firm has no specific company or management team requirements, and prefers to act as a co-investor. The firm does not require or seek board representation. As a completely strategic investor, the firm seeks to invest in companies that align with the firm’s new business goals and those that the firm can provide a strong value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a 60M Euro early-stage VC based in London. The firm invests broadly across deep tech including in healthcare and life-sciences. The team is looking for teams that are working on new and innovative technologies, the more unusual the better. The firm invests 1-2M EUR as a Seed+ round (between Seed and Series-A), often helping to bridge the gap between those rounds. The firm invests primarily in Europe, but will consider investing in companies based outside of Europe if they have a strong European connection.

The firm will consider technologies in all areas of healthcare, including therapeutics, diagnostics, drug delivery, tools, digital health and medical devices, instead focusing on the type of technology and how unique it is. They do not invest in single-asset therapeutic companies or repurposed assets. While open to all indications, the firm prefers to invest in underserved indications, such as neuroscience, infectious diseases, solid tumors, ophthalmology, and dermatology.

The firm can lead or follow in their investments. While they may take a board seat, they will only do so if it will be beneficial to the company. The firm invests in strong management teams including founder-driven companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A family office based in New York, NY is looking to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers companies that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A Japanese technology-based distributor and service solution provider of electronic components, enterprise IT and innovative solutions is headquartered in Yokohama, Japan and operates 85 offices worldwide. The firm’s main business domains lie in semiconductors, IoT and cybersecurity, but seeks to expand beyond these realms to create new businesses, including healthcare, life sciences. The firm has been making strategic investments periodically to make business partnerships with external technology startups from all around the world that align with the firm’s interests. The firm’s investment is stage agnostic but mostly between Seed and Series B financing rounds. The firm is open to business partnership and global investment opportunities from any country.

Within life sciences and healthcare, the firm is open to opportunities in digital therapeutics, devices, and digital health. Within therapeutics, the firm is primarily seeking enabling technologies in chronic diseases as diabetes, sleep disorders, mental health, and also depression and dementia. The firm will generally not consider opportunities such as pre-clinical antibody or small molecule assets that require a long window. The firm is also interested in devices (open to both 510k and PMA) or digital health technologies that are in the fields of primary care, elderly care, and mental health. Some examples of the firm’s investments include a continuous glucose monitoring device, an AI-driven robotics platform for chronic care management, and a digital therapeutics app for chronic diseases.

While the firm can invest in very early-stage companies, the firm prefers to invest in companies with a viable product that is ready to be tested in pilots or clinical trials at the earliest. The firm does not expect companies to have already received FDA approval and will help companies go through the regulatory process. Furthermore, the firm has an ongoing strategic partnership with the Japanese Organization for Medical Device Development (JOMDD), through which the firm helps companies with PMDA approval in Japan.

The firm has no specific company or management team requirements, and prefers to act as a co-investor. The firm does not require or seek board representation. As a completely strategic investor, the firm seeks to invest in companies that align with the firm’s new business goals and those that the firm can provide a strong value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

An evergreen strategic venture capital fund of a large pharma closed at $100 million in 2013 and is managed by a small, dedicated team based in Massachusetts and California. The fund focuses on investments in companies developing pioneering bioelectronic medicines/neuromodulation devices and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The firm looks for investment opportunities globally.

The firm is a fund dedicated to advancing bioelectronic medicines and is looking to invest in high-return opportunities in three areas: (1) Teams pursuing new therapies for existing peripheral neurostimulation devices. (2) Teams developing novel bioelectronic medicine technologies for existing neurostimulation therapies. (3) Companies introducing advanced technologies that are enabling for bioelectronics medicines. The firm is particularly interested in improved neural interfaces, novel power sources and wireless powering technology, ultra-low power chip architectures, sensors that can close-the-loop for adaptive therapies and new implantation and imaging methods. The firm is stage agnostic.

The firm typically will take board of directors or board observer seat, but it is not necessary. The fund exclusively invests in privately-held companies and primarily in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital arm of a global supplier of building materials as well as a manufacturer of innovative material solutions is looking for companies that will align with the Saint-Gobain strategy for either equity investments, partnerships, licensing or acquisition. Within the life sciences, the firm will consider medical devices, novel materials, diagnostics, instruments and tools. The firm is willing to invest globally, and will invest as early as prototype/proof-of-concept stage.

Within the life sciences, the firm is interested in medical device, diagnostic or instrument and tool companies. The firm will consider all medical devices, but, if FDA approval is required, the firm prefers the company to be in the approval process. For diagnostics, the firm will consider both diagnostic/monitoring machines, tools, instruments & novel materials for Genomics & Cell & Gene therapies. The firm is also interested in instruments or tools that can be used in the medical field or for research purposes.

The firm can lead or co-invest in equity investing, and their involvement in the company after investment will depend on the partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.